
|Videos|May 25, 2017
Exploring the Potential of CAR T-Cell Therapy in Head and Neck Cancer
Author(s)Sophie Papa, PhD, MBBS, MRCP
Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5






































